Adsorption type confirmatory assays

• US 6,306,616 B1
• Filed: 03/27/1998
• Issued: 10/23/2001
• Est. Priority Date: 03/27/1998
• Status: Expired due to Term

• Current Assignee: Roche Diabetes Care Inc. (Roche Holding AG)
• Original Assignee: Microgenics Corporation (Thermo Fisher Scientific Incorporated)
• Inventors: Shindelman, Jeffrey E.
• Primary Examiner(s): CEPERLEY, MARY
• Application Number:
  US09/049,464
• Time in Patent Office: 1,306 Days
• Field of Search: 435/7.93, 435/7.94, 436/546, 436/815, 436/531
• US Class Current: 435/7.93
• CPC Class Codes: G01N 33/94 involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
• CPC Class Codes: Y10S 436/815 Test for named compound or class of compounds

Abstract

The invention relates to an assay system for the improved detection of analytes, and the ability to distinguish them from cross-reacting substances. Samples giving a positive reaction in a direct assay test are treated with a neutralizing antibody that inhibits reactivity of the true analyte, but not the interfering substance. In adsorption type confirmatory assays, the neutralizing antibody is provided in an amount sufficient to adsorb the analyte but not all of the interfering substance. When retested in an immunoassay, the neutralized sample gives a negative result if it originally contained the true analyte. Samples giving a positive reaction in both the direct and confirmatory tests are marked as containing an interfering substance. The confirmatory assay easily distinguishes the true analyte and reduces the rate of false positives, even when the interfering substance is unknown and present at high concentration.

Claims

1. An assay method for distinguishing between a small molecule analyte selected from the group consisting of LSD, LSD metabolites, and combinations thereof and an interfering substance in a sample comprising the steps of:

a) preparing a reaction mixture comprising the sample, a hapten derivative that provides a signal and a detecting antibody that binds with the hapten derivative to yield a detectable signal in the assay, wherein the detecting antibody binds the hapten derivative in a manner that is specifically inhibitable by the analyte;

b) measuring the amount of the detecting antibody bound to the hapten derivative in step a);

c) treating the same sample or duplicate thereof with a neutralizing antibody in an amount sufficient to prevent the analyte but not all the interfering substance in the sample from binding the detecting antibody;

d) preparing a reaction mixture comprising the treated sample or duplicate, a hapten derivative that provides a signal, and a detecting antibody that binds with the hapten derivative to yield a detectable signal in the assay, wherein the detecting antibody binds the hapten derivative in a manner that is specifically inhibitable by the analyte;

e) measuring the amount of the detecting antibody bound to the hapten derivative in step d);

f) determining the difference in signal measured in step e) from step b); and

g) comparing the difference in signals in steps b) and e) to determine (i) the presence of analyte in the sample if the amount measured in step b) is significantly different from the amount measured in step e);

or (ii) the presence of interfering substance in the sample if the amount measured in step b) is not significantly different from the amount measured in step e).

2. The assay method of claim 1, wherein the analyte is LSD or an LSD metabolite, and the interfering substance is selected from the group consisting of methamphetamine, fenfluramine, ambroxol, ergotyptine, dihydroergotamine, ecogonine, ergonivine, ergotamine, lysergic acid, lysergol, methysergide maleate, psilocybin, psilocyn, seretonine, tryptophan, fentanyl, 2-oxo-3-hydroxy LSD, and chlorpromazine.

3. The assay method of claim 1, wherein the hapten derivatives of steps a) and d) are each a conjugate in which a hapten is linked to an enzyme, wherein the reaction mixtures of steps a) and d) further comprise a substrate for the respective enzyme, and the measuring in steps b) and e) comprises measuring enzyme catalyzed conversion of the respective substrate to a product.

4. The assay method of claim 1, wherein the hapten derivatives of steps a) and d) are each a conjugate in which a hapten is linked to an enzyme donor;

wherein the reaction mixtures of steps a) and d) further comprise both an enzyme acceptor that complements the respective enzyme donor to form an active enzyme when the detecting antibody is not bound to the hapten in the conjugate, and a substrate for the respective active enzymes; and

wherein the measuring in steps b) and e) comprises measuring enzyme catalyzed conversion of the respective substrate to a product.

5. The assay method of claim 4, wherein the same conjugate, enzyme acceptor, and substrate are used to form the reaction mixtures of steps a) and d), and the method comprises the step of measuring the relative rate of enzyme catalyzed conversion of the substrate to a product between the two reaction mixtures.

6. The assay method of claim 1, wherein the sample is a urine sample.

7. The assay method of claim 1, wherein the sample is selected from the group consisting of a serum and a plasma sample.

8. The assay method of claim 1, wherein the analyte is LSD and the interfering substance is an LSD metabolite.

9. The method according to claim 1, wherein the detecting antibody is raised against an LSD conjugate derivatized via the N−

1 position of LSD.

10. The method of claim 1, comprising removing analyte bound to the neutralizing antibody from the sample or duplicate after the treating of step c) and before the measuring of step e).

11. The assay method of claim 1, wherein the neutralizing antibody is insoluiblized.

12. The assay method of claim 1, which is a homogeneous assay.

13. The assay method of claim 1, wherein the hapten derivatives of steps a) and d) are each a hapten selected from the group consisting of a fluorescent hapten and a fluorescent quench hapten, and the measuring in steps b) and e) comprises measuring a property selected from the group consisting of fluorescence emission and fluorescence polarization.

25. The method of claim 1 wherein the analyte has a molecular weight <

1,000 daltons.

14. A kit for distinguishing between a small molecule analyte selected from the group consisting of LSD, LSD metabolites, and combinations thereof and an interfering substance in a sample in a confirmatory assay comprising:

a) a detecting antibody that binds with the analyte to give a positive reaction in the assay;

b) a neutralizing antibody that binds with the analyte to prevent the analyte from giving a positive reaction in the assay; and

c) a hapten derivative that provides a signal;

wherein the detecting antibody binds the hapten derivative in a manner that is specifically inhibitable by the analyte and the interfering substance; and

the neutralizing antibody preferentially binds the analyte in comparison with the interfering substance; and

the neutralizing antibody is in an amount sufficient to prevent the analyte in the sample from binding the detecting antibody, but not sufficient to prevent all the interfering substance in the sample from binding the detecting antibody.

15. The kit of claim 14, wherein the analyte has a molecular weight <

1,000 daltons.

16. The kit according to claim 14, wherein the detecting antibody is raised against a conjugate in which an LSD derivative is linked to a carrier through a position in the indole ring, and the kit further comprises a conjugate in which an LSD derivative is linked to a carrier through a position in the indole ring.

17. The kit according to claim 16, wherein the neutralizing antibody is raised against a conjugate in which an LSD derivative is linked to a carrier through a position in the indole ring.

18. The kit according to claims 14, wherein the neutralizing antibody is insolubilized.

19. The kit according to claim 18, wherein the detecting antibody and the neutralizing antibody are the same antibody in soluble and insolubilized form, respectively.

20. The kit according to claim 14, wherein the hapten derivative is a fluorescent hapten or a fluorescent quench hapten.

21. The kit according to claim 14, wherein the hapten derivative is a conjugate in which a hapten is linked to an enzyme or enzyme fragment, and the detecting antibody binds the hapten of the conjugate in a manner that is specifically inhibitable by the analyte.

22. The kit according to claim 14, wherein the analyte is LSD or an LSD metabolite, and the interfering substance is selected from the group consisting of methamphetamine, fenfluramine, ambroxol, and chlorpromazine.

23. A kit for adapting an immunoassay for determining a small molecule analyte selected from the group consisting of LSD, LSD metabolites, and combinations thereof in a sample to permit distinguishing between the analyte and an interfering substance wherein the immunoassay is conducted with the following reagents:

a) a detecting antibody that binds with the analyte to give a positive reaction in the assay; and

b) a hapten derivative that provides a signal;

wherein the detecting antibody binds the hapten derivative in a manner that is specifically inhibitable by the analyte and the interfering substance;

wherein the kit comprises a neutralizing antibody for the analyte to prevent the analyte from giving a positive reaction in the assay and in an amount sufficient to prevent the analyte in the sample from binding the detecting antibody, but not sufficient to prevent all the interfering substance in the sample from binding the detecting antibody.

24. The kit of claim 23 wherein the analyte has a molecular weight <

1,000 daltons.

26. The kit according to claim 23, wherein the neutralizing antibody is insolubilized.